...
首页> 外文期刊>American Journal of Translational Research >Experimental evidence and network pharmacology identify the molecular targets of Tong Sheng tablets in cerebral ischemia reperfusion injury
【24h】

Experimental evidence and network pharmacology identify the molecular targets of Tong Sheng tablets in cerebral ischemia reperfusion injury

机译:实验证据和网络药理学识别在脑缺血再灌注损伤中的桐树片的分子靶标

获取原文
           

摘要

Purpose: Tong Sheng tablets (TSTs) have long been used for treating cerebral ischemic reperfusion injury (CIRI) in clinic, but the underlying mechanism remains unknown. Therefore, in this study, TSTs were evaluated systematically using chemical analysis, network pharmacology and classical pharmacology. Methods: The first part was TSTs quality control including TSTs fingerprint establishment and chemicals identification. In the second part, network pharmacology analysis and bioinformatics were combined to construct a compound-target-disease network, which can screen out key targets or pathways, revealing complex molecule mechanism of TSTs. The last part was experiment verification. Classical pharmacology of TSTs was investigated in vivo to verify the results of network pharmacology. Results: (1) Fingerprints of TSTs were established, and 11 characteristic peaks were identified using HPLC. (2) Network pharmacology and bioinformatics suggested that the protection of TSTs in treating CIRI might be related to regulation of oxidative stress, inflammation and apoptosis, and some key molecules such as Nrf2, IL-1β, TNF, Bcl-2 and Cyt-C involved in the pathways. (3) TSTs significantly improved neurologic behavior scores, decreased the areas of ischemic necrosis and neuronal necrosis, and increased Nissl body counts. Besides, TSTs significantly decreased pro-inflammatory cytokine (IL-1β, TNF-α) and pro-oxidative product levels (LPO, MDA) and increased anti-oxidative product levels (NO, SOD). TSTs downregulated the protein expressions of Nrf2 and HO-1. Meanwhile, TSTs reduced apoptotic cell counts, downregulated the protein expressions of Cyt-C and Bax, and upregulated the protein expression of Bcl-2. In terms of autophagy, TSTs enhanced LC-3B protein expression. Conclusion: The present results illustrated that TSTs effectively alleviated CIRI, and the underlying mechanism might be associated with multiple molecular pathways. Herein, we established a primary pattern for studying Chinese herbal compounds and provided basic guidance for future investigation.
机译:目的:桐盛片(TSTS)长期以来已用于治疗临床脑缺血再灌注损伤(CIRI),但潜在机制仍然未知。因此,在本研究中,可以使用化学分析,网络药理学和古典药理学进行系统地评估TST。方法:第一部分是TSTS质量控制,包括TST指纹建立和化学品鉴定。在第二部分中,组合网络药理学分析和生物信息学,构建一种复合靶疾病网络,其可以筛选关键目标或途径,揭示TST的复杂分子机制。最后部分是实验验证。在体内研究了TST的经典药理学,以验证网络药理学的结果。结果:(1)建立了TST的指纹,使用HPLC鉴定了11个特征峰。 (2)网络药理学和生物信息学表明,TST在治疗中的保护可能与氧化应激,炎症和凋亡的调节有关,以及NRF2,IL-1β,TNF,BCL-2和CYT-C等一些关键分子参与途径。 (3)TST显着改善了神经系统行为分数,降低了缺血性坏死和神经元坏死的领域,并增加了NISSL身体计数。此外,TST显着降低了促炎细胞因子(IL-1β,TNF-α)和促氧化产物水平(LPO,MDA)和增加的抗氧化产物水平(NO,SOD)。 TST下调了NRF2和HO-1的蛋白质表达。同时,TST降低了凋亡细胞计数,下调了Cyt-C和Bax的蛋白质表达,并上调了Bcl-2的蛋白质表达。就自噬,TSTS增强了LC-3B蛋白表达。结论:本结果表明,TST有效地缓解了CIRI,并且潜在机制可能与多个分子途径相关联。在此,我们建立了研究中草化合物的主要模式,并为未来调查提供了基本指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号